By a News Reporter-Staff News Editor at Cancer Weekly -- A new study on Boron is now available. According to news reporting originating in Moscow, Russia, by NewsRx journalists, research stated, "Further development of boron neutron capture therapy (BNCT) requires new neutronsensitizers with improved ability to deliver (10)B isotopes in cancer cells. Conjugation of boron nanoparticles with porphyrin derivatives is an attractive and recognized strategy to solve this task."
The news reporters obtained a quote from the research from the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, "We report on breakthroughs in the structural optimization of conjugates of chlorin e6 derivative with cobalt-bis(dicarbollide) nanoparticles resulting in the creation of dimethyl ester 13-carbomoylchlorin e6 [N-hexylamine-N'-ethoxyethoxy]-cobalt-bis(dicarbollide) (conjugate 1). Conjugate 1 is able to accumulate quickly and efficiently (distribution factor of 80) in cancer cells, thus delivering more than 10(9) boron atoms per cell when its extracellular concentration is more than 1 ?mol L(-1). Also 1 is an active photosensitizer and is phototoxic towards human lung adenocarcinoma A549 cells at 80 nmol L(-1) (50% cell death). Photoinduced cytotoxicity of 1 is associated with lipid peroxidation, lysosome rupture and protease activity enhancement. Conjugate 1 fluoresces in the red region (670 nm), which is useful to monitor its accumulation and distribution in vivo. It is not toxic to cells without activation by neutrons or photons. Structural features that improve the functional properties of 1 are discussed."
According to the news reporters, the research concluded: "The properties of 1 warrant its preclinical evaluation as a multifunctional agent for BNCT, photodynamic therapy and fluorescent tumor diagnosis."
For more information on this research see: Chlorin e6 fused with a cobalt-bis(dicarbollide) nanoparticle provides efficient boron delivery and photoinduced cytotoxicity in cancer cells. Photochemical & Photobiological Sciences, 2014;13(1):92-102. (Royal Society of Chemistry - www.rsc.org/; Photochemical & Photobiological Sciences - pubs.rsc.org/en/journals/journalissues/pp)
Our news correspondents report that additional information may be obtained by contacting A.V. Efremenko, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, ul Miklukho-Maklaya, 16, 10, 117997 Moscow, Russia. Additional authors for this research include A.A. Ignatova, M.A. Grin, I.B. Sivaev, A.F. Mironov, V.I. Bregadze and A.V Feofanov (see also Boron).
Keywords for this news article include: Boron, Moscow, Russia, Cancer, Cobalt, Eurasia, Therapy, Oncology, Nanoparticle, Nanotechnology, Transition Elements, Emerging Technologies.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC